Conexeu Sciences (CNXU) Q3 2026 earnings summary

Executive summary

• Transitioned from a private development-stage company to a Nasdaq-listed public issuer via direct listing on May 21, 2026, with a focus on regenerative medicine and biomaterial-based technologies for tissue restoration in wound care and aesthetics.

• No revenues generated to date; operations centered on R&D, regulatory preparation, and organizational development.

• Significant expansion in business development, marketing, and personnel costs following Nasdaq listing to build market visibility and support capital-raising efforts.

Financial highlights

• Net loss for the three months ended July 31, 2026, was $7.73 million, up from $1.30 million for the same period in 2025.

• Net loss for the nine months ended July 31, 2026, was $11.75 million, compared to $2.05 million for the same period in 2025.

• Cash and cash equivalents as of July 31, 2026, were $1.97 million, down from $4.81 million at October 31, 2025.

• Accumulated deficit increased to $16.27 million as of July 31, 2026.

• No revenue recognized in the reported periods.

Outlook and guidance

• Monthly cash burn rate during the quarter was approximately $0.87 million, with current cash resources insufficient to fund operations for the next twelve months without additional financing.

• Management is actively pursuing further debt and/or equity financing; substantial doubt exists about the ability to continue as a going concern.

• Near-term objectives include advancing product development, preparing a 510(k) FDA submission (targeted for Q1 2027), and prudent management of discretionary spending.